Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Use of a Pegylated Liposome in a Phase II Trial to Enhance the Potency and Extend the Dosing Interval of Prophylactic Standard Half-Life FVIII, without Increasing the Dose

Edward Tuddenham, Gavin Ling, Richard Wolf-Garraway

Blood (2022) 140 (Supplement 1): 5586–5587.

https://doi.org/10.1182/blood-2022-170692

Published: 2022

Journal Articles

Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII

Edward Tuddenham, Richard Wolf-Garraway, Gavin Ling

Blood (2022) 140 (Supplement 1): 5617–5618.

https://doi.org/10.1182/blood-2022-170642

Published: 2022

Journal Articles

Prophylactic Treatment of Severe Haemophilia Á Patients with Inhibitors to FVIII with Peglip-FVIII

Margarita Timofeeva, Nadezhda I. Zozulya, Tatiana Pospelova, Marina V Kosinova, Igor Kurtov, Edward Tuddenham, Gavin Ling

Blood (2021) 138 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2021-149533

Published: 2021

Journal Articles

Real-World Variability in ADAMTS13 Assay Methods May Impact upon Follow up for Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Gavin Ling, Beth Brannan, Eleanor Foxton

Blood (2021) 138 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2021-150594

Published: 2021

Journal Articles

Real-World Clinical and Laboratory Characteristics in Severe Hemophilia a Patients Commencing Emicizumab

Gavin Ling, MBBS,FRCPath,PhD, Aderonke Ajidahun, RN, Steve K. Austin, BMedSci, MBBS, Gerard Dolan, MBChB, FRCP, FRCPath, Aine McCormick, PhD

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-138746

Published: 2020

Journal Articles

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Andrew Doyle, MBBS, BSc, FRPATH, Karen Breen, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia, Beverley J. Hunt, Gavin Ling, MBBS, BSc, FRCPath, Claire N Harrison, Professor, Natalia Curto Garcia, MD MBBS

Blood (2019) 134 (Supplement_1): 4183.

https://doi.org/10.1182/blood-2019-128170

Published: 2019

NARROW

The Use of a Pegylated Liposome in a Phase II Trial to Enhance the Potency and Extend the Dosing Interval of Prophylactic Standard Half-Life FVIII, without Increasing the Dose

Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII

Prophylactic Treatment of Severe Haemophilia Á Patients with Inhibitors to FVIII with Peglip-FVIII

Real-World Variability in ADAMTS13 Assay Methods May Impact upon Follow up for Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Real-World Clinical and Laboratory Characteristics in Severe Hemophilia a Patients Commencing Emicizumab

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

The Use of a Pegylated Liposome in a Phase II Trial to Enhance the Potency and Extend the Dosing Interval of Prophylactic Standard Half-Life FVIII, without Increasing the Dose

Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII

Prophylactic Treatment of Severe Haemophilia Á Patients with Inhibitors to FVIII with Peglip-FVIII

Real-World Variability in ADAMTS13 Assay Methods May Impact upon Follow up for Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Real-World Clinical and Laboratory Characteristics in Severe Hemophilia a Patients Commencing Emicizumab

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only